Rallybio Corporation
RLYB
Rank in Stocks
#20090
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to... Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoclonal anti-HPA-1a antibody currently undergoing Phase II clinical trials. This candidate, along with RLYB211, is aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company's pipeline also includes RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for addressing ophthalmic conditions driven by complement system activity. Furthermore, RLYB116, an inhibitor designed to target complement component 5 (C5) for various complement dysregulation disorders, has successfully completed its Phase 1 trial. Another preclinical antibody, RLYB332, is under investigation for treating severe anemia characterized by ineffective erythropoiesis and iron overload. Rallybio has established strategic collaborations to further its development efforts. It maintains an alliance with AbCellera for the identification, development, and commercialization of novel antibody-based therapeutics in rare diseases. Additionally, the firm partners with Exscientia on the creation of small molecule therapeutics for rare diseases, and with Johnson & Johnson to deliver therapeutic options to expectant mothers at risk of fetal and neonatal alloimmune thrombocytopenia. Established in 2018, Rallybio Corporation is headquartered in New Haven, Connecticut.
Share Price
$15.72
Last synced: 2026-11-13
Market Cap
$89.84M
Change (1 day)
0.45%
Change (1 year)
218.22%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Rallybio Corporation (RLYB)
Category
Healthcare
EPS for Rallybio Corporation (RLYB)
EPS as of September 2026 TTM: $4.61
According to Rallybio Corporation's latest financial reports, its current EPS (TTM) is $4.61. At the end of 2025 the company had an EPS of $-1.59, an increase over its 2024 EPS of $-10.64.
EPS history for Rallybio Corporation from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $4.61 | -389.94% |
| 2025 | $-1.59 | -85.06% |
| 2024 | $-10.64 | -27.72% |
| 2023 | $-14.72 | -11.96% |
| 2022 | $-16.72 | 43.15% |
| 2021 | $-11.68 | 22.69% |
| 2020 | $-9.52 | 116.36% |
| 2019 | $-4.40 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $-0.89 | -119.31% |
US
|
|
| $15.66 | 239.70% |
US
|
|
| $-7.07 | -253.36% |
US
|
|
| $-5.29 | -214.75% |
AU
|
|
| $12.73 | 176.19% |
BE
|
Questions about Rallybio Corporation's earnings per share (EPS)
What is Rallybio Corporation's earnings per share (EPS)?
Rallybio Corporation's earnings per share (EPS) over the last twelve months is $4.61, as of Sep 2026.
What was Rallybio Corporation's earnings per share (EPS) in 2025?
In 2025, Rallybio Corporation's earnings per share (EPS) was $-1.59, compared with $-10.64 in 2024.
How has Rallybio Corporation's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Rallybio Corporation's earnings per share (EPS) was highest in 2025 ($-1.59) and lowest in 2022 ($-16.72).
How does Rallybio Corporation's earnings per share (EPS) compare with similar companies?
Rallybio Corporation's earnings per share (EPS) ($4.61) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.